ACP Diabetes Monthly
Welcome to this month's issue of ACP Diabetes Monthly, an update for internists published by the American College of Physicians.
In the News for the month of October 2015
Empagliflozin associated with reduced mortality risk in patients with cardiovascular disease
Patients with type 2 diabetes and cardiovascular disease who received empagliflozin had lower rates of cardiovascular-related and all-cause mortality than those on placebo, an industry-funded study found. More...
Review compares once-weekly GLP-1 receptor agonists to other diabetes meds
Once-weekly glucagon-like peptide 1 (GLP-1) receptor agonists lower HbA1c without increasing body weight, a review found. More...
Studies offer support for home use of artificial pancreas in type 1 diabetes
Home use of a closed-loop insulin delivery system, or artificial pancreas, appeared to be effective in patients with type 1 diabetes, according to 2 recently published reports conducted under regular living conditions. More...
MKSAP quiz: Next steps in gastroparesis management
This month's quiz asks readers to evaluate a 60-year-old woman who has gastroparesis associated with long-standing type 2 diabetes mellitus. More...
From Annals of Internal Medicine
Meta-analyses look at effects of behavioral programs for diabetes
More intensive behavioral programs were more effective at helping patients with type 2 diabetes lower their HbA1c levels but not those with type 1, according to systematic analyses recently published in Annals of Internal Medicine. More...
From ACP Journal Club
Review: Type 2 diabetes screening does not reduce mortality but treating dysglycemia delays onset of diabetes
A systematic evidence review by the U.S. Preventive Services Task Force found no evidence of mortality benefit from screening for diabetes, based on 2 large randomized controlled trials conducted in the United Kingdom. More...
Warning on risks of canagliflozin
The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased bone mineral density. More...
New long-acting insulin drugs approved
Insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg 70/30) were approved by the FDA on Sept. 25. More...
Spotlight on bariatric surgery for diabetes
Recent studies assessed the impact of bariatric surgery on diabetes remission, mortality, and health care costs. More...
Physician editor: David V. O'Dell, MD, FACP
Has Your Contact Information Changed?
To change your e-mail address or other contact information in our records, go here or call 800-523-1546, ext. 2600 (M-F, 9 a.m. - 5 p.m. ET).
About ACP Diabetes Monthly
ACP Diabetes Monthly is a monthly newsletter produced by the staff of ACP Internist. It is automatically sent to all College members who have an e-mail address on file with ACP.
To add your e-mail address to your member record and to begin receiving ACP Diabetes Monthly, please click here.
Copyright © by American College of Physicians.
A 65-year-old man is evaluated after a recent colonoscopy, which disclosed a 2.5-cm pedunculated polyp in the sigmoid colon. The polyp was removed in its entirety in a single piece. Biopsy results showed a well-differentiated adenocarcinoma confined to the submucosa without evidence of lymphovascular involvement and a 1-mm margin. There is no family history of colorectal cancer. What is the most appropriate management?
Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health, 2nd Edition
This new edition reflects recent clinical and social changes and continues to present the important issues facing practitioners and their LGBT patients. Read more about the Guide. Also see ACP’s recent policy position paper on LGBT health disparities.
Join Us in Washington, DC for the Most Comprehensive Meeting in Internal Medicine
Register now and enjoy:
Discounted rates, the best national faculty, a wealth of clinical and practice management topics and hands-on sessions! Learn more about the meeting.